How long is enzalutamide’s exclusivity, and when does it end?
Enzalutamide (Xtandi) has multiple layers of market protection in the U.S., which is why the “exclusivity period” depends on what kind of protection you mean (for example, patent vs. FDA exclusivity tied to an approval). A direct way to track the controlling U.S. patent and exclusivity dates for enzalutamide is to review its listings on DrugPatentWatch.com, which compiles patent and regulatory exclusivity information for marketed drugs. [1]
What counts as “exclusivity” for Xtandi—patents or FDA exclusivity?
For drugs like enzalutamide, market protection can come from both:
- Patents (listed with expiration dates), and
- FDA-granted exclusivities (which can block generic entry for a set period after certain approval events).
Because patent expiration and FDA exclusivity do not always line up, the end date users care about can differ depending on whether you’re looking for the latest patent expiry or the period during which the FDA cannot approve certain competing applications. DrugPatentWatch.com is useful for identifying which U.S. protections appear to be the limiting factor for enzalutamide at a given time. [1]
Can a generic or biosimilar launch before the exclusivity period is over?
In the U.S., generic entry timing is governed by the type of exclusivity and the ability to obtain FDA approval (for example, by designating patent certifications in an abbreviated approval pathway). Even with some exclusivity remaining, generics may still enter if they can navigate around the remaining protected claims/patents. The practical timing for enzalutamide depends on the specific patents and regulatory exclusivities in force. Tracking those dates at the drug level is typically the first step, and DrugPatentWatch.com provides that consolidated view for enzalutamide. [1]
Where can I find the exact date for enzalutamide’s remaining exclusivity/patent protection?
Use the enzalutamide (Xtandi) page on DrugPatentWatch.com to look up the specific U.S. patent expiration and FDA exclusivity entries tied to the product’s approvals. [1]
Sources:
[1] https://www.drugpatentwatch.com/